Basic Research
Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. Jul 28, 2008; 14(28): 4462-4472
Published online Jul 28, 2008. doi: 10.3748/wjg.14.4462
Table 1 Fat pad weights (g)
LeanObeseER
ANOVA P value
ControlWhey + Ca
Subcutaneous fat0.4 ± 0.1c1.6 ± 0.11.4 ± 0.1de1.0 ± 0.1cd< 0.0001
Epididymal fat1.4 ± 0.1a1.9 ± 0.11.8 ± 0.1f1.3 ± 0.05b0.0006
Perirenal fat0.7 ± 0.1c1.3 ± 0.11.4 ± 0.1df0.9 ± 0.1b< 0.0001
Table 2 Incidences of the observed histopathological lesions in liver samples
LeanObeseER
ControlWhey + Ca
Number of samples8101010
No abnormalities detected8000
Macrovesicular fatty change (total)0101010
Severe0100
Marked0100
Moderate0554
Slight0355
Minimal0001
Infiltration of inflammatory cells, minimal0113
Focal hepatocyte necrosis, total0202
Slight0100
Minimal0102
Table 3 Concentrations of primary metabolites in liver samples (&mgr;mol/g tissue)
LeanObeseER
ANOVA P value
ControlWhey + Ca
Glucose-6-phosphate28.6 ± 2.7a19.2 ± 3.522.7 ± 1.7h11.2 ± 3.2f< 0.0001
Fructose-6-phosphate7.0 ± 0.74.9 ± 0.66.9 ± 0.7h3.2 ± 0.9e0.001
Mannose-6-phosphate1.7 ± 0.21.7 ± 0.21.4 ± 0.1g0.8 ± 0.2cf0.0003
Fructose bisphosphate3.2 ± 0.68.7 ± 2.09.5 ± 2.4dh0.5 ± 0.1b0.0005
Glycerate-3-phosphate26.2 ± 3.721.0 ± 0.817.4 ± 1.2d13.1 ± 1.4f0.0008
Ribose-5-phosphate0.3 ± 0.02a0.7 ± 0.10.7 ± 0.1di1.3 ± 0.1cf< 0.0001
Succinate24.5 ± 3.3c5.3 ± 1.16.7 ± 2.4fi24.0 ± 4.0c< 0.0001
Malate42.0 ± 5.2a54.5 ± 3.761.3 ± 4.7dg40.5 ± 5.1a0.008
Citrate4.9 ± 0.7c2.0 ± 0.31.6 ± 0.2f1.8 ± 0.3f< 0.0001
Pyruvate5.6 ± 0.8c0.9 ± 0.22.6 ± 0.4e1.5 ± 0.3f< 0.0001
Phosphoenolpyruvate2.8 ± 0.82.3 ± 0.31.4 ± 0.21.2 ± 0.20.0426
6-phosphogluconate3.5 ± 0.2a2.4 ± 0.23.7 ± 0.2eg2.6 ± 0.4a0.0023
Fumarate9.6 ± 1.0a10.4 ± 1.117.8 ± 1.7bfg11.9 ± 1.3a0.0003